Blade Therapeutics

OverviewSuggest Edit

Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Blade’s novel target biology was discovered by its founder, Hal Dietz, M.D., Victor A. McKusick Professor of Genetics and Medicine, Johns Hopkins University. Blade licensed intellectual property associated with Dr. Dietz’s work and is advancing new compounds to halt the progression of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. By targeting novel pathways common to multiple fibrotic disease states, we believe we can build the leading company in anti-fibrotic drug discovery and development. Blade has assembled scientific and leadership teams with unparalleled experience. Our scientific team as well as our Board have extensive expertise in fibrosis and the discovery and development of anti-fibrotic drugs. Blade’s scientific advisory board includes world renowned experts in the pathobiology of fibrotic disease.
TypePrivate
Founded2015
HQSouth San Francisco, CA, US
Websiteblademed.com

Recent NewsAll News

Latest Updates

Cybersecurity ratingAMore

Key People/Management at Blade Therapeutics

Wendye Robbins

Wendye Robbins

Director, President & CEO
Jean-Frédéric Viret

Jean-Frédéric Viret

Chief Financial Officer
Prabha Ibrahim

Prabha Ibrahim

Chief Technology Officer
Maria Fuentes

Maria Fuentes

Executive Vice President of Research
Felix Karim

Felix Karim

Executive Vice President of Business Development
Daven Mody

Daven Mody

Vice President of Regulatory Affairs
Show more

Blade Therapeutics Office Locations

Blade Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
442 Littlefield Ave
Show all (1)

Blade Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Blade Therapeutics total Funding

$51.5 m

Blade Therapeutics latest funding size

$45 m

Time since last funding

5 years ago

Blade Therapeutics investors

Blade Therapeutics's latest funding round in June 2016 was reported to be $45 m. In total, Blade Therapeutics has raised $51.5 m
Show all financial metrics

Blade Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Blade Therapeutics Online and Social Media Presence

Embed Graph

Blade Therapeutics News and Updates

VC-backed Blade Therapeutics hires EVP of research

South San Francisco-based Blade Therapeutics, a biopharmaceutical company that treats fibrotic disease, has appointed Dr. Maria E. Fuentes as executive vice president of research. Previously, she was group director of fibrosis discovery biology at Bristol-Myers Squibb. Blade's backers include MPM Ca…

Blade Therapeutics Frequently Asked Questions

  • When was Blade Therapeutics founded?

    Blade Therapeutics was founded in 2015.

  • Who are Blade Therapeutics key executives?

    Blade Therapeutics's key executives are Wendye Robbins, Jean-Frédéric Viret and Prabha Ibrahim.

  • Who are Blade Therapeutics competitors?

    Competitors of Blade Therapeutics include Particular Sciences, Phenomenex and Althea.

  • Where is Blade Therapeutics headquarters?

    Blade Therapeutics headquarters is located at 442 Littlefield Ave, South San Francisco.

  • Where are Blade Therapeutics offices?

    Blade Therapeutics has an office in South San Francisco.

  • How many offices does Blade Therapeutics have?

    Blade Therapeutics has 1 office.